AASLD (The Liver Meeting)

-
San Francisco
,
United States of America

A poster will be presented at this event demonstrating that the baseline combination of HBcrAg and HBsAg titers may help to apply a personalized treatment in HBeAg negative chronic hepatitis B patients and to evaluate the HBsAg loss likelihood (poster title: "The baseline combination of HBcrAg and HBsAg titers enhance treatment outcome and HBsAg loss predictions in HBeAg negative chronic hepatitis B patients treated with pegylated interferon alfa-2a or PegIFN plus Tenofovir-disoproxil-fumarate").

Several highly interesting abstracts on our Lumipulse PIVKA and HBcrAg assays will be presented as well.

Please contact us to find out more.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.